Taking HIV Testing

to a New Level
Download Poster

Bio-Rad is pleased to introduce the BioPlex 2200 HIV Ag-Ab assay,

the first 5th generation diagnostic test for HIV infection.
What differentiates 5th generation from 4th generation?
The ability to differentiate HIV-1 antibodies, HIV-2 antibodies and HIV-1 p24 antigen
The ability to differentiate acute from established HIV infection
By allowing simultaneous detection and differentiation of the three markers, the BioPlex 2200 HIV Ag-Ab assay
delivers more information to healthcare providers. The BioPlex 2200 HIV Ag-Ab assay offers additional benefits to
laboratories, including long specimen stability, lab and workflow consolidation, and quality assurance. Confident
results can guide supplemental testing.
The BioPlex 2200 HIV Ag-Ab assay is a multiplex flow immunoassay intended for the simultaneous qualitative
detection and differentiation of the three individual analytes in a single reaction. The indications for use include
pediatrics two years or older and pregnant women. It can be used for testing plasma samples from solid organ donors
or for testing serum or plasma from living subjects. It is not intended for routine use in screening blood or plasma
donors.
WARNING: FDA has approved this test for use with serum and plasma specimens only. Use of this test kit with
specimens other than those specifically approved for use with this test kit may result in inaccurate test results.
This test is not intended for use in children younger than 2 years of age.

A European study published in peer-reviewed Journal of Clinical Microbiology* reports an excellent performance with
high sensitivity and high specificity.
The BioPlex 2200 HIV Ag-Ab assay is considered a new generation of test due to its HIV differentiation capability.
With the enhanced capability of the BioPlex 2200 5th generation HIV assay, results can be used to help navigate
through the latest CDC HIV testing algorithm, enabling earlier detection of acute HIV infection.
Backed by cutting-edge multiplex technology and proven clinical performance, laboratories can be confident in their
HIV testing results.
By quickly identifying an important puzzle piece, the BioPlex 2200 HIV Ag-Ab assay detects, differentiates and gives a
full picture of the type and extent of the disease. Early detection can guide supplemental testing for infected patients to
seek treatment, as well as enable outreach to others who may have been infected, thus reducing further transmissions.
Early detection saves lives.
Bio-Rad Your authority in HIV testing.

Download Poster

*Published in JCM- January 2014, Vol. 52, No. 1, p. 103-107 (Salmona, et al, including Professor Francois Simon)
Copyright 2015 Bio-Rad Laboratories, Inc. All rights reserved.